Podcast: Play in new window | Download (Duration: 1:16:46 — 105.6MB) | Embed
Subscribe: Apple Podcasts | Spotify | Amazon Music | Android | Pandora | iHeartRadio | Blubrry | Podcast Index | Email | TuneIn | RSS | More
Dive into the research that Robin and his team have done in-house and their secret sauce, as well as exploring the current state of research on senescent cell elimination and its potential impact on healthspan and lifespan. Robin will also share his thoughts on the development pipeline for Deciduous Therapeutics’ immune mediated senolysis drugs, and how they differ from other companies in the field of immune mediated senolysis.
Robin Mansukhani links
https://www.linkedin.com/in/robin-mansukhani-8633653/
PODCAST INFO:
The Learning With Lowell show is a series for the everyday mammal. In this show we’ll learn about leadership, science, and people building their change into the world. The goal is to dig deeply into people who most of us wouldn’t normally ever get to hear. The Host of the show – Lowell Thompson- is a lifelong autodidact, serial problem solver, and founder of startups.
LINKS
Youtube: https://www.youtube.com/channel/UCzri06unR-lMXbl6sqWP_-Q
Youtube clips: https://www.youtube.com/channel/UC-B5x371AzTGgK-_q3U_KfA
Linkedin: https://www.linkedin.com/in/lowell-thompson-2227b074
Twitter: https://twitter.com/LWThompson5
Website: https://www.learningwithlowell.com/
Timestamps / chapters
00:00 Intro Robin Mansukhani
00:45 Defensibility of Deciduous Therapeutics IP
03:25 Buying vs building
05:00 Altos labs
06:00 Time horizon for Deciduous Therapeutics therapies
07:25 Blockers
10:00 Stage of current therapies
11:05 Highs and lows of Deciduous Therapeutics
13:45 Muscle of grit
15:25 Strategies for when feeling low
17:10 Ice baths
19:25 Reading to ground
20:45 Different perspectives
21:45 Hands on leading
24:45 Listening to understand
26:25 Developing multiple drugs
28:45 When to stop developing new drugs
30:10 T-Cells, senescence
34:30 T cell natural response to senescent cells
35:45 Fibrosis, type 2 diabetes therapy and model
39:00 Type 1 and type 2 diabetes
40:25 Immune response to t-cell therapy
41:25 Resistance and down regulation
44:05 Dosage over time
44:45 Drug interactions / mono therapy
46:45 Drug to drug interactions
49:15 Cutting edge research / data on in-house research on t-cells and senescence
54:00 Health span and life span
55:45 Vision for future
58:15 Different compared to other senescence / longevity related companies
1:01:45 Platform / future of ”startup”
1:03:30 Mapping future when research can be flawed
1:06:00 Books
1:09:20 On the lookout for people who’ve brought drugs to market
1:10:30 Ways to stay up to date
1:11:35 Managing Investor relations